Table 3.
Univariate and multivariate analyses of the factors for overall survival in the entire cohort
| Variable | Univariate | Multivariate | ||
|---|---|---|---|---|
| Hazard ratio (95% CI) | P | Hazard ratio (95% CI) | P | |
| Age – per 1 yr | 0.99 (0.98‒1.00) | 0.046 | 0.99 (0.98‒1.00) | 0.15 |
| Male sex | 1.33 (0.93‒1.89) | 0.12 | ||
| Treatment location | 0.049 | < 0.001 | ||
| North America | Reference | Reference | ||
| Asia | 1.35 (1.00‒1.84) | 3.80 (2.03‒7.10) | ||
| BMI – per 1 kg/m2 | 0.98 (0.95‒1.02) | 0.28 | ||
| Previous treatment | 0.61 (0.47‒0.78) | < 0.001 | 0.58 (0.42‒0.81) | 0.001 |
| Etiology of liver disease | 0.07 | 0.35 | ||
| HBV | Reference | Reference | ||
| Hepatitis C virus | 1.22 (0.82‒1.82) | 2.02 (1.02‒3.99) | ||
| Alcohol | 0.93 (0.56‒1.53) | 1.34 (0.67‒2.69) | ||
| NAFLD | 0.65 (0.34‒1.22) | 1.19 (0.55‒2.60) | ||
| Others or unknown | 0.59 (0.37‒0.92) | 1.13 (0.56‒2.25) | ||
| Cirrhosis | 1.34 (1.04‒1.72) | 0.024 | 1.09 (0.82‒1.47) | 0.55 |
| ECOG PS, 1 or higher | 1.52 (1.20‒1.94) | < 0.001 | 1.33 (1.00‒1.76) | 0.049 |
| Lymphocyte, per 100/μL | 0.98 (0.96‒1.00) | 0.014 | ||
| Monocyte, per 100/μL | 1.08 (1.03‒1.15) | 0.005 | ||
| LM ratio, per 1 unit | 0.88 (0.81‒0.95) | 0.001 | 0.88 (0.81‒0.97) | 0.007 |
| Platelet, per 10000/μL | 1.01 (1.00‒1.03) | 0.10 | ||
| Albumin, per 1 g/dL | 0.46 (0.36‒0.59) | < 0.001 | ||
| Bilirubin, per 1 mg/dL | 1.30 (1.18‒1.43) | < 0.001 | ||
| ALT, per 1 IU/L | 1.00 (1.00‒1.01) | 0.10 | ||
| PT INR, per 1 unit | 4.77 (2.83‒8.04) | < 0.001 | ||
| Creatinine, per 1 mg/dL | 0.91 (0.66‒1.25) | 0.54 | ||
| Log10AFP, per 1 ng/mL | 1.12 (1.08‒1.16) | < 0.001 | 1.25 (1.13‒1.38) | < 0.001 |
| HBV DNA, 20,000 IU/mL or higher | 1.36 (0.92‒2.00) | 0.13 | ||
| Tumor characteristics | < 0.001 | 0.72 | ||
| Nodular lesion(s) | Reference | Reference | ||
| No liver lesion | 0.62 (0.45‒0.85) | 0.87 (0.61‒1.25) | ||
| Infiltrative lesion(s) | 1.39 (1.06‒1.82) | 1.01 (0.69‒1.49) | ||
| Portal vein thrombosis | 1.78 (1.40‒2.27) | < 0.001 | 1.27 (0.91‒1.78) | 0.17 |
| Lymph node metastasis | 1.33 (0.98‒1.79) | 0.07 | 1.50 (1.05‒2.13) | 0.025 |
| Distant metastasis | 0.99 (0.76‒1.29) | 0.96 | ||
| CP score, per 1 point | 1.34 (1.20‒1.49) | < 0.001 | 1.19 (1.03‒1.38) | 0.017 |
CI, confidence interval; BMI, body mass index; HBV, hepatitis B virus; NAFLD, non-alcoholic fatty liver disease; ECOG PS, Eastern Cooperative Oncology Group Performance Status; LM ratio, lymphocyte/monocyte ratio; ALT, alanine aminotransferase; PT, prothrombin time; INR, international normalized ratio; AFP, alpha-fetoprotein; CP score, Child-Pugh score.